| Novartis–Astellas: micafungin, 202110– acquisition of ww product rights to Mycamine/Funguard by Sandoz from Astellas SIGNED |
2023-01-24 |
| DeuterOncology–Andrew Lloyd Associates: public relations, 202301 service existent by ALA |
2023-01-19 |
| Agilent–Plasmion: ionisation technology, 202301– collab co-marketing of SICRIT ion source with Agilent Ultivo LC/TQ + LC/MSD iQ MS systems |
2023-01-18 |
| Blackford Analysis–Bayer: investment, 202301– acquisition by Bayer ANNOUNCED |
2023-01-18 |
| Siemens–ASG Superconductors: magnetic resonance imaging, 202301– collab integration of ASG MRI magnets >7T in Siemens Healthineers UFH MRI systems |
2023-01-18 |
| Flame Biosciences–Leap Therapeutics: investment, 202301 merger acquisition of Flame Biosciences Inc by Leáp Therapeutics Inc |
2023-01-17 |
| InDevR–Adjuvant Capital: investment, 202301 financing round Series B totalling $9m incl $4m from Adjuvant Capital |
2023-01-17 |
| InDevR–Mérieux: investment, 202301 financing round Series B totalling $9m incl $5m from bioMérieux in connection w partnership |
2023-01-17 |
| InDevR–SEVERAL: investment, 202301 financing round Series B $9m from bioMérieux + Adjuvant Capital |
2023-01-17 |
| Mérieux–InDevR: VaxArray platform, 202301– excl distribution of VaxArray portfolio by bioMérieux in Europe |
2023-01-17 |
| Bayer–Alphabet: cloud computing services, 202301– collab using Google Cloud TPUs for quantum chemitry calculations in drug discovery |
2023-01-11 |
| NextPoint Therapeutics–Bayer: investment, 202301 financing round Series B totalling $80m incl new + co-lead investor Leaps by Bayer |
2023-01-10 |
| NextPoint Therapeutics–Catalio Capital: investment, 202301 financing round Series B totalling $80m incl new + co-investor Catalio Capital Management |
2023-01-10 |
| NextPoint Therapeutics–Harvard Univ: investment, 202301 financing round Series B totalling $80m incl existing + co-investor Binney Street Capital |
2023-01-10 |
| NextPoint Therapeutics–Invus Group: investment, 202301 financing round Series B totalling $80m incl new + co-investor Invus |
2023-01-10 |
| NextPoint Therapeutics–MPM Capital: investment, 202301 financing round Series B totalling $80m incl existing + co-investor MPM Capital Management |
2023-01-10 |
| NextPoint Therapeutics–PagodaTree Partners: investment, 202301 financing round Series B totalling $80m incl new + co-investor PagodaTree Partners |
2023-01-10 |
| NextPoint Therapeutics–PERSON: investment, 202301 financing round Series B totalling $80m incl existing + co-investor + co-founder Gordon Freeman |
2023-01-10 |
| NextPoint Therapeutics–Sanofi: investment, 202301 financing round Series B totalling $80m incl new + co-lead investor Sanofi Ventures |
2023-01-10 |
| NextPoint Therapeutics–SEVERAL: investment, 202301 financing round Series B $80m co-led by Leaps by Bayer + Sanofi Ventures |
2023-01-10 |
| NextPoint Therapeutics–Sixty Degree Capital: investment, 202301 financing round Series B totalling $80m incl new + co-investor Sixty Degree Capital |
2023-01-10 |
| Albireo–Ipsen: investment, 202301– cash tender offer $952m at $42/share plus 1 CVR/share entitling to $10/CVR |
2023-01-09 |
| Boehringer–3T Biosciences: cancer immunotherapies, 202301– strategic collab + license agreem RnD of cancer therapies using 3T-TRACE discovery platform |
2023-01-09 |
| Delta Precision–Astrea Bioseparations: investment, 202301 acquisition of Delta Precision Ltd by Astrea |
2023-01-09 |
| Proteros–Inflexion: investment, 202301– minority investment by Inflexion with founder + CEO Torsten Neuefeind remaing majority shareholder + CEO |
2023-01-09 |
| Verogen–Qiagen: investment, 202301c full acquisition of Verogen for $150m in cash |
2023-01-09 |
| Amryt Pharma–Chiesi: investment, 202301– acquisition $1.25b upfront cash for all ADSs plus CVRs representing potential $225m consideration ANNOUNCED |
2023-01-08 |
| Synthekine–Column Group: investment, 202301 financing round round Series C totalling $100m incl existing + lead investor The Column Group |
2023-01-06 |
| Synthekine–SEVERAL: investment, 202301 financing round round Series C $100m led by The Column Group with new + existing investors |
2023-01-06 |
| Acquifer Imaging–Bruker: investment, 202201 acquisition €na of Acquifer Imaging Gmbh + subsidiary Deltabyte GmbH by Bruker |
2023-01-05 |
| Akamis Bio–ARCH Venture: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor ARCH Venture Partners |
2023-01-05 |
| Akamis Bio–Parker Institute: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor Parker Institute |
2023-01-05 |
| Akamis Bio–SEVERAL: credit, 202301 convertible note financing $30m co-led by ARCH Venture + Parker Institute + Westalke Village BioPartners |
2023-01-05 |
| Akamis Bio–Westlake Village BioPartners: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor Westlake Village BP |
2023-01-05 |
| Asimov–Andreessen Horowitz: investment, 202301 financing round Series B totalling $175m incl existing + co-investor a16z |
2023-01-05 |
| Asimov–Casdin Capital: investment, 202301 financing round Series B totalling $175m incl co-investor Casdin Capital |
2023-01-05 |
| Asimov–CPPIB: investment, 202301 financing round Series B totalling $175m incl lead investor CPP Investments |
2023-01-05 |
| Asimov–Fidelity: investment, 202301 financing round Series B totalling $175m incl co-investor Fidelity Management and Research Company |
2023-01-05 |
| Asimov–Horizon Ventures: investment, 202301 financing round Series B totalling $175m incl existing + co-investor Horizon Ventures |
2023-01-05 |
| Asimov–KdT Ventures: investment, 202301 financing round Series B totalling $175m incl co-investor KDT |
2023-01-05 |
| Asimov–Pillar: investment, 202301 financing round Series B totalling $175m incl co-investor Pillar |
2023-01-05 |
| Asimov–SEVERAL: investment, 202301 financing round Series B $175m led by CPP Investments |
2023-01-05 |
| BioVersys–AMR Action Fund: investment, 202301 financing round Series C extension with CHF8.2m? from AMR AF bringing total Series C to CHF32.6m |
2023-01-05 |
| Volta Medical–Gilde Investment: investment, 202301 fianncing round Series B totalling €36m incl existing + co-investor Gilde Healthcare |
2023-01-05 |
| Volta Medical–Lightstone Ventures: investment, 202301 fianncing round Series B totalling €36m incl new + co-investor Lightstone Ventures |
2023-01-05 |
| Volta Medical–SEVERAL: investment, 202301 fianncing round Series B €36m led by Vensana Capital |
2023-01-05 |
| Volta Medical–Vensana Capital: investment, 202301 fianncing round Series B totalling €36m incl new + lead investor Vensana Capital |
2023-01-05 |
| Biognosys–Bruker: investment, 202301 acquisition €na of majority share in Biognosys by Bruker |
2023-01-04 |
| Hummingbird Bioscience–Synaffix: ADC technology, 202301– license to GlycoConnect + HydraSpace + toxSYN technoligies up to $150m plus royalties |
2023-01-04 |
| Cellectis–EU (govt): credit, 202212– credit facility up to €40m in 3 tranches from EIB to develop allogeneic CAR T-cell products |
2022-12-28 |
| Merck (US)–Kelun Pharmaceuticals: antibody-drug conjugates, 202212– collab + license ww excl $175m upfront + $9.3b milestones for 7 ADCs for cancer |
2022-12-22 |
| Torreya–Stifel: investment, 202212– acquisition €na of Torreya Partners LLC by Stifel ANNOUNCED |
2022-12-22 |
| Ganymede Bio–Caffeinated Capital: investment, 202212 financing round Series A totalling $12.75m incl lead investor Caffeinated Capital |
2022-12-20 |
| Ganymede Bio–SEVERAL: investment, 202212 financing round Series A $12.75m led by Caffeinated Capital |
2022-12-20 |
| Tmunity Therapeutics–Gilead: investment, 202212– acquisition €na excluding PSMA + PSCA assets by Kite ANNOUNCED |
2022-12-20 |
| Boehringer–Click Therapeutics: digital therapeutics, 202212– collab expansion to develop 2nd DTx for schizophrenia up to $460m + royalties |
2022-12-19 |
| Minervax–SEVERAL: investment, 202212 financing round €22m co-led by Trill Impact Ventures + Pureos Bioventures |
2022-12-15 |
| Storm Therapeutics–Fast Track Initiative: investment, 202212 financing round Series B totalling $30m incl new + co-lead investor FTI |
2022-12-14 |
| Storm Therapeutics–Pfizer: investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor Pfizer Ventures |
2022-12-14 |
| Storm Therapeutics–SEVERAL: investment, 202212 financing round Series B $30m led by M Ventures + Pfizer Ventures + Taiho Ventures + CIC |
2022-12-14 |
| BehaVR–Accenture Ventures: investment, 202212 financing round Series B totalling $13m incl co-investor Accenture Ventures |
2022-12-13 |
| BehaVR–Chrysalis Ventures: investment, 202212 financing round Series B totalling $13m incl co-investor Chrysalis Ventures |
2022-12-13 |
| BehaVR–Confluent Health: investment, 202212 financing round Series B totalling $13m incl co-investor Confluent Health |
2022-12-13 |
| BehaVR–Oxford Science Enterprises: investment, 202212 financing round Series B totalling $13m incl co-lead investor Oxford Science Enterprises |
2022-12-13 |
| BehaVR–SEVERAL: investment, 202212 financing round Series B $13m led by Optum Ventures + Oxford Science Enterprises |
2022-12-13 |
| BehaVR–Thornton Capital: investment, 202212 financing round Series B totalling $13m incl co-investor Thornton Capital |
2022-12-13 |
| BehaVR–UnitedHealth: investment, 202212 financing round Series B totalling $13m incl co-lead investor Optum Ventures |
2022-12-13 |
| Oxford VR–BehaVR: investment, 202211 merger under BehaVR brand |
2022-12-13 |
| Horizon Therapeutics–Amgen: investment, 202212– acquisition recommended cash offer $27.8b for all outstanding shares at $116.5/share |
2022-12-12 |
| MyCellHub–SEVERAL: investment, 202212 financing round €2m with Gemma Frisius Fund + Noshaq + The Factory Fund + LRM |
2022-12-08 |
| Cellesce–Danaher: investment, 202212 acquisition of Cellesce by Molecular Devices |
2022-12-06 |
| Entact Bio–SEVERAL: investment, 202212 financing round Series A $81m co-led by Qiming Venture Partners USA + venBio Partners |
2022-12-06 |
| Erbi Biosytems–Merck (DE): investment, 202212 acquisition €na of Erbi Biosystems by Merck |
2022-12-01 |
| Intellia Therapeutics–SEVERAL: investment, 202211–202212 public offering $300m+$45m with 6.55m+983k shares at $45.8/share |
2022-11-30 |
| BMS–Envisagenics: AI-based drug discovery, 202211– collab multi-year using SpliceCore AI platform to discover new oncology targets |
2022-11-29 |
| Cajal Neuroscience–Alexandria Real Estate: investment, 202211 financing round Series A totalling $96m incl co-investor Alexandria Venture Investments |
2022-11-29 |
| Cajal Neuroscience–BMS: investment, 202211 financing round Series A totalling $96m incl co-investor BMS |
2022-11-29 |
| Cajal Neuroscience–Column Group: investment, 202211 financing round Series A totalling $96m incl co-lead investor The Column Group |
2022-11-29 |
| Cajal Neuroscience–Dolby Family Ventures: investment, 202211 financing round Series A totalling $96m incl co-investor Dolby Family Ventures |
2022-11-29 |
| Cajal Neuroscience–Evotec: investment, 202211 financing round Series A totalling $96m incl existing + co-investor Evotec |
2022-11-29 |
| Cajal Neuroscience–Lux Capital: investment, 202211 financing round Series A totalling $96m incl co-lead investor Lux Capital |
2022-11-29 |
| Cajal Neuroscience–SEVERAL: investment, 202211 financing round Series A $96m led by The Column Group + Lux Capital |
2022-11-29 |
| Cajal Neuroscience–Ten Bridge Communications: public relations, 202211 service existent Ten Bridge is media contact |
2022-11-29 |
| Cajal Neuroscience–Two Sigma Ventures: investment, 202211 financing round Series A totalling $96m incl co-investor Two Sigma Ventures |
2022-11-29 |
| Focus-X Therapeutics–Full-Life Technologies: investment, 202211– acquisition up to $245m of Focux-X by Full-Life Technologies ANNOUNCED |
2022-11-29 |
| Genezen–Ramarketing: public relations, 202211 service existent Ramarketing is media contact |
2022-11-29 |
| Neogene Therapeutics–AstraZeneca: investment, 202211–202301 acquisition $200m upfront + $120 milestones on cash/debt free basis |
2022-11-29 |
| Rgenta Therapeutics–AstraZeneca: investment, 202211 financing round Series A totalling $52m incl new + lead investor AZ-CICC Fund |
2022-11-29 |
| Rgenta Therapeutics–Delos Capital: investment, 202211 financing round Series A totalling $52m incl new + co-investor Delos Capital |
2022-11-29 |
| Rgenta Therapeutics–Korean Investment Partners: investment, 202211 financing round Series A totalling $52m incl new + co-investor Korean IP |
2022-11-29 |
| Rgenta Therapeutics–SEVERAL: investment, 202211 financing round Series A $52m led by AZ-CICC Healthcare Investment Fund |
2022-11-29 |
| Touchlight–Gates Foundation: grant, 202211– grant to advance pre-clinical development of doggybone DNA vaccine platform |
2022-11-29 |
| Biomemory–SEVERAL: investment, 202211 seed financing round €5m led by eureKARE + French Tech Seed Fund |
2022-11-28 |
| Strand Therapeutics–FPV Ventures: investment, 202211 financing round Series A extension totalling $45m incl new + lead investor VPF Ventures |
2022-11-28 |
| Strand Therapeutics–KKH Advisors: public relations, 202211 service existent by KKH Advisors |
2022-11-28 |
| Strand Therapeutics–Lilly: investment, 202211 financing round Series A extension totalling $45m incl new + co-investor Eli Lilly |
2022-11-28 |
| Strand Therapeutics–OTHER: investment, 202211 financing round Series A extension totalling $45m incl undisclosed syndicate |
2022-11-28 |
| Strand Therapeutics–Playground Global: investment, 202211 financing round Series A extension totalling $45m incl existing + co-investor PG |
2022-11-28 |
| Strand Therapeutics–Potentum Partners: investment, 202211 financing round Series A extension totalling $45m incl new + co-investor Potentum Partners |
2022-11-28 |
| Strand Therapeutics–SEVERAL: investment, 202211 financing round Series A extension $45m led by FPV Ventures bringing total round to $97m |
2022-11-28 |
![[LSUS] Life-Sciences-USA.com - The Transatlantic Life Sciences Web Portal](/images/basics/lsus-life-sciences-usa-portal-logo-2019.png){kind=logo}
Date![Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x200px](/banner/iito-business-intelligence-20220406-650-200-lse-life-sciences-europe.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
